Literature DB >> 33272370

Hemodynamic and Clinical Implications of Impaired Pulmonary Vascular Reserve in the Fontan Circulation.

Alexander C Egbe1, William R Miranda2, Jason H Anderson2, Barry A Borlaug2.   

Abstract

BACKGROUND: Pulmonary vascular disease, pulmonary endothelial dysfunction, liver fibrosis, renal disease, and exercise intolerance are common in adults with Fontan physiology. Although the pathophysiologic mechanisms linking these phenomena have been studied, certain aspects are not well understood.
OBJECTIVES: This study hypothesized that impaired pulmonary vascular reserve (VR) plays a central role linking these abnormalities, and that patients with abnormal pulmonary VR with exercise, compared with patients with normal VR, would display poorer pulmonary endothelial function, greater liver stiffness, more renal dysfunction, and poorer exercise capacity.
METHODS: Symptomatic adults with the Fontan palliation (n = 29) underwent invasive cardiopulmonary exercise testing, echocardiography, and assessment of microvascular function. Abnormal pulmonary VR was defined by the slope of increase in pulmonary pressure relative to cardiac output with exercise >3 mm Hg/l/min. Pulmonary endothelial function was assessed using reactive hyperemia index. End-organ function was assessed using magnetic resonance elastography-derived liver stiffness, glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, and peak oxygen consumption (Vo2).
RESULTS: Compared with individuals with normal VR (n = 8), those with abnormal VR (n = 21) displayed higher central and pulmonary venous pressures, and more severely impaired cardiac output and stroke volume responses to exertion, but similar pulmonary vascular resistance at rest. Patients with abnormal VR displayed more severely impaired reactive hyperemia index, increased liver stiffness, lower glomerular filtration rate, higher N-terminal pro-B-type natriuretic peptide, and lower peak Vo2. As compared to pulmonary vascular resistance at rest, slope of increase in pulmonary pressure relative to cardiac output displayed stronger correlations with reactive hyperemia index (r = -0.63 vs. r = -0.31; Meng test p = 0.009), magnetic resonance elastography-derived liver stiffness (r = 0.47 vs. r = 0.29; Meng test p = 0.07), glomerular filtration rate (r = -0.52 vs. r = -0.24; Meng test p = 0.03), N-terminal pro-B-type natriuretic peptide (r = 0.56 vs. r = 0.17; Meng test p = 0.02), and peak Vo2 (r = -0.63 vs. r = -0.26; Meng test p = 0.02).
CONCLUSIONS: Pulmonary vascular limitations in Fontan physiology are related to pulmonary endothelial and end-organ dysfunction, suggesting a mechanistic link between these commonly observed findings, and these abnormalities are more apparent during exercise testing, with little relationship at rest.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fontan physiology; cardiopulmonary exercise test; endothelial dysfunction; pulmonary vascular disease; pulmonary vascular reserve

Mesh:

Year:  2020        PMID: 33272370      PMCID: PMC7720935          DOI: 10.1016/j.jacc.2020.10.003

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


  27 in total

1.  Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation.

Authors:  S Khambadkone; J Li; M R de Leval; S Cullen; J E Deanfield; A N Redington
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

2.  Impaired vascular function in patients with Fontan circulation.

Authors:  Seon Mi Jin; Chung Il Noh; Eun Jung Bae; Jung Yun Choi; Yong Soo Yun
Journal:  Int J Cardiol       Date:  2006-12-18       Impact factor: 4.164

Review 3.  Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases.

Authors:  Gregory D Lewis; Eduardo Bossone; Robert Naeije; Ekkehard Grünig; Rajeev Saggar; Patrizio Lancellotti; Stefano Ghio; Janos Varga; Sanjay Rajagopalan; Ronald Oudiz; Melvyn Rubenfire
Journal:  Circulation       Date:  2013-09-24       Impact factor: 29.690

4.  Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Garvan C Kane; Vojtech Melenovsky; Thomas P Olson
Journal:  Eur Heart J       Date:  2016-06-26       Impact factor: 29.983

5.  Mechanism for temporal changes in exercise capacity after Fontan palliation: Role of Doppler echocardiography.

Authors:  Alexander Egbe; Arooj R Khan; William R Miranda; Naser M Ammash; Carole A Warnes; Sameh S Said; Nathaniel W Taggart; Emmanuel Akintoye; Gruschen R Veldtman; Heidi M Connolly
Journal:  Am Heart J       Date:  2017-10-22       Impact factor: 4.749

6.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Thomas P Olson; Carolyn S P Lam; Kelly S Flood; Amir Lerman; Bruce D Johnson; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2010-09-07       Impact factor: 24.094

7.  Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.

Authors:  T S Rector; J N Cohn
Journal:  Am Heart J       Date:  1992-10       Impact factor: 4.749

8.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 9.  Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.

Authors:  I F Ghalayini
Journal:  Int J Impot Res       Date:  2004-12       Impact factor: 2.896

10.  Venous congestion and pulmonary vascular function in Fontan circulation: Implications for prognosis and treatment.

Authors:  Alexander C Egbe; Yogesh N V Reddy; Arooj R Khan; Mohamad Al-Otaibi; Emmanuel Akintoye; Masaru Obokata; Barry A Borlaug
Journal:  Int J Cardiol       Date:  2018-11-15       Impact factor: 4.164

View more
  4 in total

Review 1.  Invasive Hemodynamic Evaluation of the Fontan Circulation: Current Day Practice and Limitations.

Authors:  Ashish H Shah; Shakeel A Qureshi; Richard A Krasuski
Journal:  Curr Cardiol Rep       Date:  2022-03-01       Impact factor: 2.931

Review 2.  Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review.

Authors:  Steven Hsu; James C Fang; Barry A Borlaug
Journal:  J Card Fail       Date:  2021-08-10       Impact factor: 5.712

Review 3.  Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)-Rationale and Design.

Authors:  Derek L Tran; Hannah Gibson; Andrew J Maiorana; Charlotte E Verrall; David W Baker; Melanie Clode; David R Lubans; Diana Zannino; Andrew Bullock; Suzie Ferrie; Julie Briody; Peter Simm; Vishva Wijesekera; Michelle D'Almeida; Sally E Gosbell; Glen M Davis; Robert Weintraub; Anthony C Keech; Rajesh Puranik; Martin Ugander; Robert Justo; Dominica Zentner; Avik Majumdar; Leeanne Grigg; Jeff S Coombes; Yves d'Udekem; Norman R Morris; Julian Ayer; David S Celermajer; Rachael Cordina
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

Review 4.  Late Fontan Circulatory Failure. What Drives Systemic Venous Congestion and Low Cardiac Output in Adult Fontan Patients?

Authors:  Alexander Van De Bruaene; Guido Claessen; Thomas Salaets; Marc Gewillig
Journal:  Front Cardiovasc Med       Date:  2022-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.